Home › Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes
 

Keywords :   


Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes

2014-06-13 14:00:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. New Research Initiative Seeks to Identify Unmet Needs and Address Key Gaps in the Management of Type 2 Diabetes WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of a global registry to evaluate the experiences and outcomes of approximately 20,000 patients with type 2 diabetes in real-world settings over three years. The registry is part of Mercks new global research initiative evaluating outcomes of patients with type 2 diabetes in everyday clinical practice. Language: English Contact: Media:Pam Eisele267-305-3558orKim Hamilton908-423-6831 / 908-391-0131orInvestors:Justin Holko908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: type research global expanded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
15.06Atlantic Tropical Weather Outlook
15.06Eastern North Pacific Tropical Weather Outlook
15.06This Week in Agribusiness, June 15, 2024
15.06Atlantic Tropical Weather Outlook
More »